← All organizations
Highest phase reached
Phase 4
First clinical trial
May 2, 2002First marketed drug
Dec 21, 2017First NDA
Dec 21, 2017Last known activity
Dec 31, 2023
Acquired by Innovive Pharmaceuticals → CytRx on Jul 11, 2022
Timeline
1980s
- Jul 1, 1989
La Jolla Pharmaceutical Company— Founded
2000s
- Sep 22, 2008
CytRx— Now
2010s
- Dec 21, 2017
angiotensin ii— NDA Organization
- Dec 21, 2017
angiotensin ii— NDA Secondary Org
2020s
- Jul 11, 2022
Innovive Pharmaceuticals— Acquired By
Drugs by trial phase (9 distinct, 24 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Autoimmune Diseases
- beta-Thalassemia
- Glomerulonephritis
- Hemochromatosis
- Hepatorenal Syndrome
- Hypotension
- Immune System Diseases
- Iron Overload
- Kidney Diseases
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Nephritis
- Renal Insufficiency, Chronic
- Shock
- Shock, Surgical
- Syndrome
- Thalassemia
Marketed drugs (1)
Recent trials (28)
- NCT03245528Lead sponsorN/A—
- NCT06122987CollaboratorPhase 4Dec 31, 2023
- NCT05824767CollaboratorPhase 4Apr 17, 2023
- NCT05193370CollaboratorPhase 4Jan 3, 2022
- NCT04901169CollaboratorPhase 2/Phase 3Jan 1, 2022
- NCT04904562CollaboratorPhase 4Jun 15, 2021
- NCT04529005CollaboratorPhase 4Aug 13, 2020
- NCT03623529Lead sponsorPhase 2Aug 31, 2018
- NCT03431077Lead sponsorPhase 2Feb 11, 2018
- NCT03381833Lead sponsorPhase 2Nov 30, 2017
- NCT03395704Lead sponsorPhase 2Nov 29, 2017
- NCT02338843Study directorPhase 3Mar 1, 2015
- NCT02338843Lead sponsorPhase 3Mar 1, 2015
- NCT02312050Lead sponsorPhase 2Mar 1, 2015
- NCT02312050Study directorPhase 2Mar 1, 2015
Details
- Founded
- San Diego, CA, US Jul 1, 1989
- First NDA
- Dec 21, 2017
- Last known activity
- Dec 31, 2023
Designations held
- Priority review